# A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus 

Source: https://onco.cc/trials/nct04224493/  
OnCo record `nct04224493` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Tazemetostat, Lenalidomide, Rituximab in follicular lymphoma, run by Epizyme, Inc., active and no longer recruiting.

## Summary

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. is a phase 3 interventional study registered as NCT04224493 by Epizyme, Inc., with 599 participants enrolled, started 2020-06-11 and due to reach its primary completion in 2027-02-13. Interventions recorded: Tazemetostat, Tazemetostat, Placebo oral tablet, Lenalidomide, Rituximab. Conditions listed: Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04224493
- Phase: 3
- Setting: Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma
- Sponsor: Epizyme, Inc.
- Enrolled: 599

## Sources

- ClinicalTrials.gov NCT04224493: https://clinicaltrials.gov/study/NCT04224493

## Connected records

- cancers: [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/)
- drugs: [Lenalidomide](https://onco.cc/drugs/lenalidomide/), [Rituximab](https://onco.cc/drugs/rituximab/), [Tazemetostat](https://onco.cc/drugs/tazemetostat/)
- companies: [Ipsen](https://onco.cc/companies/ipsen/)

---
JSON: https://onco.cc/api/v1/entities/nct04224493.json